European Heart Journal最新文献_第6页

Treatment and outcomes of chronic coronary syndromes: the EORP EURECA imaging registry. 慢性冠状动脉综合征的治疗和结果：EORP EURECA成像登记。

IF 35.6 1区医学

European Heart Journal Pub Date : 2025-10-14 DOI: 10.1093/eurheartj/ehaf594

Riccardo Liga, Alessia Gimelli, Tomaž Podlesnikar, Marta Cvijić, Gianluca Pontone, Marcelo Haertel Miglioranza, Andrea Igoren Guaricci, Sara Seitun, Alberto Clemente, Alexey Sumin, João Vitola, Antti Saraste, Christian Paunonen, Ching-Hui Sia, Filipp Paleev, Leyla Elif Sade, Jose Luis Zamorano, Natallia Maroz-Vadalazhskaya, Mirjana Sredojević, Constantinos Anagnostopoulos, Filipe Macedo, Juhani Knuuti, Thor Edvardsen, Bernard Cosyns, Steffen E Petersen, Julien Magne, Cecile Laroche, Bogdan A Popescu, Victoria Delgado, Danilo Neglia

引用次数: 0

Lessons from coronary physiology: primum non nocere. 从冠状动脉生理学的教训：原始的非中心。

IF 35.6 1区医学

European Heart Journal Pub Date : 2025-10-14 DOI: 10.1093/eurheartj/ehaf429

Adrian P Banning

引用次数: 0

DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry. Impella治疗急性心肌梗死相关性心源性休克的危险休克标准和结果：J-PVAD登记

IF 39.3 1区医学

European Heart Journal Pub Date : 2025-10-13 DOI: 10.1093/eurheartj/ehaf787

Riku Arai,Keisuke Kojima,Daisuke Fukamachi,Yasuo Okumura

{"title":"DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry.","authors":"Riku Arai,Keisuke Kojima,Daisuke Fukamachi,Yasuo Okumura","doi":"10.1093/eurheartj/ehaf787","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf787","url":null,"abstract":"BACKGROUND AND AIMSThe DanGer shock trial showed a survival benefit of Impella in highly selected patients with ST-elevation myocardial infarction-related cardiogenic shock (STEMI-CS). In real-world settings, however, Impella is often used in broader populations not meeting trial criteria. This study aimed to assess the distribution and outcomes of DanGer shock-eligible and -ineligible acute myocardial infarction-related cardiogenic shock (AMI-CS) patients in a nationwide Japanese registry.METHODSA total of 3975 AMI-CS patients treated with Impella between 2020 and 2023 were identified from the J-PVAD registry. Patients were stratified into five groups: eligible STEMI-CS, non-eligible STEMI-CS, out-of-hospital cardiac arrest (OHCA), mechanical complications (MCs), and non-STEMI-CS (NSTEMI-CS). Eligible STEMI-CS was defined as STEMI-CS fulfilling all of the following: lactate ≥ 2.5 mmol/L, systolic blood pressure <100 mmHg or catecholamine use, left ventricular ejection fraction <45%, and shock onset to first Impella support ≤24 h. Thirty-day mortality, associated risk factors, and complications were examined across the five groups.RESULTSEligible STEMI-CS accounted for 35.6% of all AMI-CS cases, with a 30-day mortality of 37.6%. Non-eligible STEMI-CS patients had lower mortality (27.6%), but it increased significantly with advanced age, renal dysfunction, veno-arterial extracorporeal membrane oxygenation use, ventricular arrhythmia, or sepsis. Thirty-day mortality was 51.3% in OHCA (63.4% without return of spontaneous circulation), 39.8% in MC, and 33.3% in NSTEMI-CS groups.CONCLUSIONSIn this nationwide registry, one-third of AMI-CS patients treated with Impella met DanGer shock criteria. Outcomes in non-eligible subgroups were heterogeneous, highlighting the importance of individualized risk assessment in guiding Impella use in real-world practice.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"50 2 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145277249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The management of heart failure: a brief look into the future. 心力衰竭的管理：对未来的简要展望。

IF 39.3 1区医学

European Heart Journal Pub Date : 2025-10-13 DOI: 10.1093/eurheartj/ehaf720

Eugene Braunwald

引用次数: 0

Multidisciplinary meetings to provide the best cardiovascular care: the European Society for Clinical Investigation. 提供最佳心血管护理的多学科会议：欧洲临床研究学会。

IF 39.3 1区医学

European Heart Journal Pub Date : 2025-10-13 DOI: 10.1093/eurheartj/ehaf739

Luca Liberale,Gemma Vilahur,Federico Carbone

引用次数: 0

An unexpected secondary iliac-enteric fistula after endovascular repair of a tuberculous-infected iliac pseudoaneurysm. 在血管内修复结核感染的髂假性动脉瘤后发生意外的继发性髂肠瘘。